In an open letter, drugmaker Eli Lilly declared that it 'stands against the use of its medicines for cosmetic weight loss' despite the drugs being used off-label for weight loss purposes, making the company billions of dollars.
Lilly emphasizes that Zepbound and Mounjaro should only be used as per FDA approval, meant for those who are overweight and have weight-related conditions like diabetes, cautioning against usage for cosmetic weight loss or by those with gastrointestinal disorders like pancreatitis.
[
add
]
[
|
|
...
]